JJ
MRNA icon

JDC-JSC’s Moderna MRNA Stock Holding History

JDC-JSC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$502K Buy
+7,100
New +$495K 2.41% 15

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JDC-JSC's MRNA Position: Q3 2020 in Review

JDC-JSC opened a new position in Moderna (MRNA) in Q3 2020: 7,100 shares worth $502K. The stake represents 2.41% of the portfolio and ranks #15 among its holdings.

548 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • JDC-JSC held 7,100 shares of Moderna worth $502K as of Q3 2020.
  • Moderna was a new JDC-JSC position in Q3 2020.
  • Moderna made up 2.41% of JDC-JSC's portfolio in Q3 2020, its #15 holding.
  • 548 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on JDC-JSC's 13F filing for Q3 2020, filed 3 Nov 2020.